Outpatient Management of Pediatric Heart Failure

Heart Failure Clinics

Volumn 6, Issue 4, 2010, Pages 515-529

  O'Connor, Matthew J ^a,b   Rosenthal, David N ^c,d   Shaddy, Robert E ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Heart failure; Management; Outpatient; Pediatric; Therapy

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENALAPRIL; EPLERENONE; INOTROPIC AGENT; METOPROLOL; MILRINONE; NESIRITIDE; NORADRENALIN; PERINDOPRIL; SPIRONOLACTONE; VASOPRESSIN;

CARDIAC RESYNCHRONIZATION THERAPY; CHILD; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DEVICE THERAPY; DIAPHORESIS; DISEASE CLASSIFICATION; DYSPNEA; HEALTH CARE DELIVERY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MITRAL VALVE REGURGITATION; MORTALITY; OUTPATIENT CARE; PEDIATRIC CARDIOLOGY; PRIMARY PREVENTION; PULMONARY HYPERTENSION; REVIEW; SURVIVAL TIME; SYMPTOM; TACHYPNEA; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; AMBULATORY CARE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOTONIC AGENTS; CHILD; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DIGOXIN; DIURETICS; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS;

EID: 77956940782     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2010.05.007     Document Type: Review

References (112)

1. Rosenthal D., Chrisant M.R., Edens E., et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004, 23:1313-1333.
2. Harmon W.G., Sleeper L.A., Cuniberti L., et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol 2009, 104:281-286.
3. Wang J., Nagueh S.F. Current perspectives on cardiac function in patients with diastolic heart failure. Circulation 2009, 119:1146-1157.
4. Lester S.J., Tajik A.J., Nishimura R.A., et al. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol 2008, 51:679-689.
5. Jerosch-Herold M., Kwong R.Y. Magnetic resonance imaging in the assessment of ventricular remodeling and viability. Curr Heart Fail Rep 2008, 5:5-10.
6. Assomull R.G., Pennell D.J., Prasad S.K. Cardiovascular magnetic resonance in the evaluation of heart failure. Heart 2007, 93:985-992.
7. Karamitsos T.D., Francis J.M., Myerson S., et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol 2009, 54:1407-1424.
8. Goldsmith S.R. Treatment options for hyponatremia in heart failure. Heart Fail Rev 2009, 14:65-73.
9. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818-827.
10. Anand I.S. Anemia and chronic heart failure: implications and treatment options. J Am Coll Cardiol 2008, 52:501-511.
11. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005, 112:e154-e235.
12. Heart Failure Society of America Nonpharmacologic management and health care maintenance in patients with chronic heart failure. J Card Fail 2006, 12:e29-e37.
13. Maisel A., Mueller C., Adams K., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008, 10:824-839.
14. Koch A., Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003, 89:875-878.
15. Mir T.S., Marohn S., Laer S., et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002, 110:e76.
16. Yoshibayashi M., Kamiya T., Saito Y., et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995, 133:207-209.
17. Ationu A., Carter N.D. Brain and atrial natriuretic peptide plasma concentrations in normal healthy children. Br J Biomed Sci 1993, 50:92-95.
18. Maher K.O., Reed H., Cuadrado A., et al. B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics 2008, 121:e1484-e1488.
19. Tan L.H., Jefferies J.L., Liang J.F., et al. Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the intensive care unit. Cardiol Young 2007, 17:397-406.
20. Price J.F., Thomas A.K., Grenier M., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006, 114:1063-1069.
21. Mavinkurve-Groothuis A.M., Kapusta L., Nir A., et al. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 2008, 25:655-664.
22. Kaski J.P., Tome-Esteban M.T., Mead-Regan S., et al. B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy. Heart 2008, 94:1307-1311.
23. Geiger M., Harake D., Halnon N., et al. Screening for rejection in symptomatic pediatric heart transplant recipients: the sensitivity of BNP. Pediatr Transplant 2008, 12:563-569.
24. Bernus A., Wagner B.D., Accurso F., et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009, 135:745-751.
25. Clark A.M., Savard L.A., Thompson D.R. What is the strength of evidence for heart failure disease-management programs?. J Am Coll Cardiol 2009, 54:397-401.
26. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
27. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
28. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
29. Kawano H., Do Y.S., Kawano Y., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130-1137.
30. Konstam M., Kronenberg M., Rousseau M., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993, 88:2277-2283.
31. Gring C.N., Francis G.S. A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol 2004, 44:1841-1846.
32. McMurray J.J., Östergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003, 362:767-771.
33. Lakhdar R., Al-Mallah M.H., Lanfear D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14:181-188.
34. Shaddy R.E., Teitel D.F., Brett C. Short-term hemodynamic effects of captopril in infants with congestive heart failure. Am J Dis Child 1988, 142:100-105.
35. Bengur A., Beekman R., Rocchini A., et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991, 83:523-527.
36. Calabro R., Pisacane C., Pacileo G., et al. Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J 1999, 138:955-961.
37. Kouatli A.A., Garcia J.A., Zellers T.M., et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997, 96:1507-1512.
38. Duboc D., Meune C., Lerebours G., et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005, 45:855-857.
39. Duboc D., Meune C., Pierre B., et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007, 154:596-602.
40. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
41. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002, 20:4517-4522.
42. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
43. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation 2009, 119:1977-2016.
44. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348:2007-2018.
45. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000, 283:1295-1302. for the MERIT-HF Study Group.
46. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999, 353:9-13.
47. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658. for the Carvedilol Prospective Randomized Cumulative Survival Study Group.
48. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807-2816.
49. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
50. Remme W.J., Poole-Wilson P., Swedberg K., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7.
51. Shaddy R.E., Tani L.Y., Gidding S.S., et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999, 18:269-274.
52. Bruns L.A., Chrisant M.K., Lamour J.M., et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001, 138:505-511.
53. Williams R.V., Tani L.Y., Shaddy R.E. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 2002, 21:906-909.
54. Azeka E., Franchini Ramires J.A., Valler C., et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002, 40:2034-2038.
55. Rusconi P., Gomez-Marin O., Rossique-Gonzalez M., et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004, 23:832-838.
56. Blume E.D., Canter C.E., Spicer R., et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006, 27:336-342.
57. Shaddy R.E., Boucek M.M., Hsu D.T., et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007, 298:1171-1179.
58. Foerster S.R., Canter C.E. Pediatric heart failure therapy with beta-adrenoceptor antagonists. Paediatr Drugs 2008, 10:125-134.
59. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258-2262.
60. Rhodes J., Margossian R., Darras B.T., et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008, 29:343-351.
61. Kajimoto H., Ishigaki K., Okumura K., et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006, 70:991-994.
62. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
63. Kimball T.R., Daniels S.R., Meyer R.A., et al. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am J Cardiol 1991, 68:1377-1382.
64. Greenberg B., Zannad F., Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol 2006, 97:34F-40F.
65. Eapen Z., Rogers J.G. Strategies to attenuate pathological remodeling in heart failure. Curr Opin Cardiol 2009, 24:223-229.
66. Davis K.L., Nappi J.M. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clin Ther 2003, 25:2647-2668.
67. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
68. Bozkurt B., Agoston I., Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003, 41:211-214.
69. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
70. Mahle W.T., Wang A., Quyyumi A.A., et al. Impact of spironolactone on endothelial function in patients with single ventricle heart. Congenit Heart Dis 2009, 4:12-16.
71. Pitt B. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. Heart 2009, 95:1205-1208.
72. Hauptman P.J., Mikolajczak P., George A., et al. Chronic inotropic therapy in end-stage heart failure. Am Heart J 2006, 152:e1-e8.
73. Young J.B., Moen E.K. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 2000, 19:S49-S57.
74. Cesario D., Clark J., Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998, 135:121-129.
75. Berg A.M., Snell L., Mahle W.T. Home inotropic therapy in children. J Heart Lung Transplant 2007, 26:453-457.
76. Cripe L.H., Barber B.J., Spicer R.L., et al. Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy. Neuromuscul Disord 2006, 16:745-748.
77. Abraham W.T. Cardiac resynchronization therapy. Prog Cardiovasc Dis 2006, 48:232-238.
78. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321:406-412.
79. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991, 324:781-788.
80. The Cardiac Arrhythmia Suppression Trial II Investigators Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227-233.
81. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995, 333:77-82.
82. Amiodarone Trials Meta-Analysis Investigators Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997, 350:1417-1424.
83. Piepoli M., Villani G.Q., Ponikowski P., et al. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. Int J Cardiol 1998, 66:1-10.
84. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
85. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576-1584.
86. Connolly S.J., Gent M., Roberts R.S., et al. Canadian Implantable Defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000, 101:1297-1302.
87. Kuck K., Cappato R., Siebels J., et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. Circulation 2000, 102:748-754.
88. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933-1940.
89. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
90. Buxton A.E., Lee K.L., Fisher J.D., et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882-1890.
91. Myerburg R.J. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 2008, 359:2245-2253.
92. Epstein A.E. Benefits of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2008, 52:1122-1127.
93. Tung R., Zimetbaum P., Josephson M.E. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008, 52:1111-1121.
94. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol 2008, 51:e1-62.
95. Berul C.I. Defibrillator indications and implantation in young children. Heart Rhythm 2008, 5:1755-1757.
96. Berul C.I., Van Hare G.F., Kertesz N.J., et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008, 51:1685-1691.
97. Stephenson E.A., Batra A.S., Knilans T.K., et al. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. J Cardiovasc Electrophysiol 2006, 17:41-46.
98. Hsia T.Y., Bradley S.M., LaPage M.J., et al. Novel minimally invasive, intrapericardial implantable cardioverter defibrillator coil system: a useful approach to arrhythmia therapy in children. Ann Thorac Surg 2009, 87:1234-1238.
99. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
100. Cleland J.G.F., Daubert J., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
101. Jarcho J.A. Biventricular pacing. N Engl J Med 2006, 355:288-294.
102. Linde C., Abraham W.T., Gold M.R., et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008, 52:1834-1843.
103. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361:1329-1338.
104. Nagueh S.F. Mechanical dyssynchrony in congestive heart failure: diagnostic and therapeutic implications. J Am Coll Cardiol 2008, 51:18-22.
105. Chung E.S., Leon A.R., Tavazzi L., et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation 2008, 117:2608-2616.
106. Dubin A.M., Janousek J., Rhee E., et al. Resynchronization therapy in pediatric and congenital heart disease patients. J Am Coll Cardiol 2005, 46:2277-2283.
107. Cecchin F., Frangini P.A., Brown D.W., et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. J Cardiovasc Electrophysiol 2009, 20:58-65.
108. Janousek J., Vojtovic P., Hucin B., et al. Resynchronization pacing is a useful adjunct to the management of acute heart failure after surgery for congenital heart defects. Am J Cardiol 2001, 88:145-152.
109. Zimmerman F.J., Starr J.P., Koenig P.R., et al. Acute hemodynamic benefit of multisite ventricular pacing after congenital heart surgery. Ann Thorac Surg 2003, 75:1775-1780.
110. Janousek J., Gebauer R.A., Abdul-Khaliq H., et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009, 95:1165-1171.
111. Friedberg M.K., Roche S.L., Balasingam M., et al. Evaluation of mechanical dyssynchrony in children with idiopathic dilated cardiomyopathy and associated clinical outcomes. Am J Cardiol 2008, 101:1191-1195.
112. Canter C.E., Shaddy R.E., Bernstein D., et al. Indications for heart transplantation in pediatric heart disease. Circulation 2007, 115:658-676.